Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Acute Erythroid Leukemia
- Acute Megakaryoblastic Leukemia
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Acute Myeloid Leukemia in Remission
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Blasts Under 20 Percent of Bone Marrow Nucleated Cells
- Blasts Under 20 Percent of Peripheral Blood White Cells
- Chronic Myelomonocytic Leukemia
- High Risk Myelodysplastic Syndrome
- Myelodysplastic Syndrome
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Therapy-Related Acute Myeloid Leukemia
- Therapy-Related Myelodysplastic Syndrome
Interventions
- BIOLOGICAL: Aldesleukin
- BIOLOGICAL: Allogeneic CD56-positive CD3-negative Natural Killer Cells
- PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation
- DRUG: Busulfan
- DRUG: Fludarabine Phosphate
- OTHER: Laboratory Biomarker Analysis
- PROCEDURE: Peripheral Blood Stem Cell Transplantation
- OTHER: Pharmacological Study
Sponsor
M.D. Anderson Cancer Center
Collaborators